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ABSTRACT
Hodgkin lymphoma (HL) and primary mediastinal B-cell lymphoma (PMBL) 
share similar molecular features by gene expression profiling. Frequent gains of 
chromosome 9p exhibit higher Janus Kinase 2 (JAK2) transcript levels with increased 
JAK2 activity, suggesting aberrant activity of JAK2 and STAT pathways. This signaling 
pathway alteration may in part play an important role in the pathogenesis and/or 
chemoradiotherapy resistance in HL and PMBL. Ruxolitinib is a potent and selective 
JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) 
including those harboring the JAK2V617F mutation. We investigated the in vitro and 
in vivo efficacy of ruxolitinib and changes in downstream signaling pathways in HL 
and PMBL. We demonstrated that ruxolitinib significantly inhibited STAT signaling 
in both HL and PMBL with constitutively active JAK2 signaling. We also observed 
that ruxolitinib significantly induced in vitro anti-proliferative effects (p < 0.05) 
and increased programmed cell death (p < 0.05) against both HL and PMBL cells. 
Importantly, ruxolitinib significantly inhibited tumor progression by bioluminescence 
(p < 0.05) and significantly improved survival in HL (p = 0.0001) and PMBL (p < 
0.0001) xenograft NSG mice. Taken altogether, these studies suggest that ruxolitinib 
may be a potential adjuvant targeted agent in the therapeutic approach in patients 
with high risk HL and PMBL. 
www.impactjournals.com/oncotarget/                   Oncotarget, 2018, Vol. 9, (No. 11), pp: 9776-9788
INTRODUCTION
Hodgkin lymphoma (HL) and primary mediastinal 
large B-cell lymphoma (PMBL) are two of the most 
common malignancies among adolescents and young 
adults (AYA). HL and PMBL share similar molecular 
features [1, 2]. HL has a bimodal age distribution, with a 
first peak at 15–35 years of age and second peak after 50 
years of age [3]. Although HL represents approximately 
4–5% of all cancers in children younger than 15 years 
of age, HL is the most common cancer in the 15–35 
years AYA group, with an incidence of about 16% [4]. 
The prognosis is excellent in AYA with HL, with 10 
year overall survival rates approximately 85–95% [5]. 
However, patients with an early relapse (≤12 months from 
diagnosis) and/or have metastatic extra-nodal disease 
at relapse/progression have a dismal prognosis [6, 7]. 
Furthermore, there are significant late effects secondary to 
chemo-radiotherapy in patients with HL, including cardiac 
and pulmonary toxicity, infertility and increased risk of 
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secondary malignancy, which affect the long-term event-
free survival (EFS) especially in AYA [8, 9]. Therefore, 
new targeted agents are needed to avoid late effects in HL 
and improve the outcomes in patients with high risk of 
relapse/progression. 
PMBL was previously considered a subtype of 
diffuse large B-cell lymphoma (DLBCL) and is now 
classified as distinct mature B-cell lymphoma [10]. 
PMBL is a rare malignancy that, although more common 
among adults in their third and fourth decades of life, is 
also commonly seen in AYA, with a female predominance 
[4, 11–13]. PMBL represents approximately 4% of mature 
B-cell non-Hodgkin lymphoma in patients ≤18 years of age 
[14–17]. Although considered a mature B-cell lymphoma, 
we have identified that children and adolescents with 
newly diagnosed PMBL have a significantly decreased 
EFS compared to children and adolescents with other 
forms of DLBCL treated with similar therapy [16]. HL 
and PMBL also share similar cytogenetic abnormalities, 
namely chromosome 9p and 2p gains [18, 19] including 
rearrangement of chromosome 13 [20, 21]. Gain in 9p has 
been demonstrated to be associated with an upregulation 
in the expression of the Janus Kinase (JAK) 2 (JAK2) 
gene in about 50% of patients, leading to phosphorylation 
and activation of transcription factor signal transducer and 
activator of transcription (STAT) 6 [2, 22, 23]. Gain in 
2p16 region has been associated with duplication of REL 
proto-oncogene that encodes for nuclear factor kappa B 
(NFKB) transcription factor [22]. PTPN1 mutations have 
also been shown recently in both HL and PMBL, leading 
to hyper-phosphorylation in JAK-STAT pathway [24]. 
HL and PMBL thus exhibit higher JAK2 transcript levels 
with increased JAK2 activity [25], suggesting aberrant 
activity of JAK2 and STAT pathways may in part play 
an important role in the pathogenesis and/or resistance in 
AYA HL and PMBL. Inhibition of JAK2 by fedratinib in 
HL and mediastinal large B-cell lymphoma (MLBL) has 
been significantly associated with an inhibition of cell 
proliferation and decreased growth in MLBL xenografted 
non-obese diabetic severe combined immunodeficiency 
gamma (NSG) mice, further establishing the importance 
of JAK2 activation in these tumors [26]. 
The role of JAK2 inhibitors like ruxolitinib and 
fedratinib has been studied in patients with myelofibrosis 
and myeloproliferative neoplasms (MPNs) that 
consistently exhibit dysregulation of the JAK1/JAK2 
pathway [27–29]. Ruxolitinib is a potent and selective 
ATP-competitive inhibitor of JAK1 and JAK2 kinases 
against MPNs including those with a JAK2V617F mutation. 
Ruxolitinib also inhibits JAK2/STAT5 signaling in vitro 
and in murine models of MPNs [30]. It is worthy to note 
that ruxolitinib is associated with marked and durable 
clinical benefits in patients with myelofibrosis [31]. 
Interestingly the clinical benefit in MPN patients was 
achieved irrespective of JAK2V617F status, which suggests 
that the pathophysiological consequence of hyperactivity 
of the JAK/STAT pathway can be downregulated with 
ruxolitinib therapy [32]. 
We hypothesize that ruxolitinib may potentially 
be an effective therapeutic agent, in part by inducing 
targeted programmed cell death in both HL and PMBL. 
Therefore, we investigated the in vitro and in vivo 
efficacy of ruxolitinib against HL and PMBL cells in 
an immunodeficient mouse model (NSG) xenografted 
with human HL and PMBL and its in-vitro effects on 
downstream protein signaling pathways.
RESULTS
Effect of ruxolitinib on the JAK2/STAT signaling 
pathway in HL cells
The effect of ruxolitinib on the JAK2/STAT signaling 
pathways was examined measuring the phosphorylation 
status of JAK2 and its downstream substrates in HL cell 
lines. First, we observed that increasing concentrations of 
ruxolitinib (10-100 nM) for 24 h significantly inhibited 
downstream active phosphorylated STAT3 (p-STAT3, p 
< 0.005 at 10 nM, and p < 0.0005 at 25 - 100 nM) and 
phosphorylated STAT5 (p-STAT5, p < 0.005 at 10 nM, 
p < 0.0005 at 25 nM, and p < 0.0001 at 50 and 100 nM) 
in a dose-dependent manner in HDLM-2 cells (Figure 1A 
and 1C), whereas, total STAT3 and STAT5 levels remained 
unchanged at the concentrations up to 100 nM (Figure 
1B and 1D). Similarly, no differences in expression of 
p-STAT3 and p-STAT5 were observed at different time 
points up to 100 nM ruxolitinib treated HDLM-2 cells at 
48 and 72 hours (Data not shown). The dose escalation 
of ruxolitinib demonstrated an increase of the level 
of phosphorylated JAK2 (p-JAK2) in HDLM-2 cells. 
Conversely, we found no inhibitory effects of ruxolitinib 
at concentrations up to 100 nM in another HL cell line, 
L-540, which contains constitutively-active forms of 
JAK3, but not JAK2. In contrast, the pan-JAK inhibitor 
AG490 non-selectively inhibited the phosphorylation 
levels of these p-JAK2, p-STAT3 and p-STAT5 tested 
in both of HDLM-2 cells and L-540 cells. These results 
suggest that ruxolitinib inhibits JAK2/STAT signaling by 
blocking of downstream of the phosphorylation of STAT3 
and STAT5 and that ruxolitinib shows selective activity of 
JAK2 against JAK3 in HL cell lines which is consistent 
with other studies suggesting that ruxolitinib is a JAK1/
JAK2 inhibitor with marked selectivity over JAK3.
Effect of ruxolitinib on phosphorylation of 
STAT-3, -5 and -6 in HL and PMBL cells 
To investigate the effects of ruxolitinib on the 
JAK2/STAT pathway in HL and PMBL cells, L-428 and 
HDLM-2 HL cells, and Karpas-1106P PMBL cells, each 
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were treated with vehicle (dimethyl sulfoxide [DMSO]) 
alone or ruxolitinib (0, 25, 100, 400 and 1000 nM) for 
48 hours and western blots were performed. Ruxolitinib 
significantly downregulated phosphorylation of STAT3, 
STAT5 and STAT6 in L-428 (Figure 2A and Figure 2D), 
HDLM-2 (Figure 2B and Figure 2E) following 25 nM 
ruxolitinib treatment compared to DMSO control whereas 
the expression level of total STAT3, STAT5 and STAT6 
did not significantly change. Similarly, we observed 
significant inhibition of phosphorylation of STAT3 and 
STAT6 in 25 nM ruxolitinib treated Karpas-1106P cells 
(Figure 2C and Figure 2F). However, there was no 
significant inhibition of phosphorylation of STAT5 in 
Karpas-1106P following ruxolitinib treatment. 
Significant anti-proliferative in vitro effects of 
ruxolitinib in HL and PMBL cells 
We examined the effect of ruxolitinib on HL and 
PMBL in vitro cell proliferation. Cells were treated 
with vehicle (DMSO) alone or ruxolitinib at various 
concentrations (0, 1, 10, and 100 uM) for 48 hours and cell 
proliferation was determined using MTS assay. There was 
a significant decrease in cell proliferation in the ruxolitinib 
treated L-428, HDLM-2 and Karpas-1106P vs control 
cells with DMSO treatment (20 - 79% reduction, p-value 
between p < 0.05 and p < 0.01) (Figure 3A). Specifically, 
there were significant decreases in cell proliferation with 
20% reduction (p < 0.01) and 64% reduction (p < 0.01) 
with 10 and 100 uM of ruxolitinib treatment, respectively, 
in ruxolitinib treated L-428 cells. We also observed 
significant inhibition of cell proliferation with 38% (p 
< 0.05), 49% (p < 0.01) and 79% (p < 0.01) reduction 
in 1, 10 and 100 uM ruxolitinib treated HDLM-2 cells, 
respectively, compared to DMSO treated control cells. 
Ruxolitinib treated Karpas-1106P cells also showed 
significant inhibition with 20% (p < 0.05), 44% (p < 
0.05) and 59% (0 < 0.05) reduction in 1, 10 and 100 
uM ruxolitinib treated Karpas-1106P cells, respectively, 
compared to control cells following DMSO treatment.
Significant increase in ruxolitinib-induced 
caspase-3/7 activity
To further investigate the mechanisms of the anti-
proliferative activity of ruxolitinib, we determined the 
caspase-3/7 activity in ruxolitinib treated HL and PMBL 
cells. HL and PMBL cells were evaluated for fold change 
of caspase 3/7 activity over 48 hours with escalating doses 
of ruxolitinib (0, 1, 10 and 100 uM) (Figure 3B). There 
Figure 1: Selective activity of ruxolitinib on the JAK2/STAT signaling pathway in HL cells. Ruxolitinib (0, 10, 25, 50, and 
100 nM) treated HDLM-2 and L-540 HL cells were collected and the lysates were separated in SDS-PAGE gels (A and B, respectively). 
The pan-JAK inhibitor, AG490 was used as a negative control treatment in each cell. Significant differences of p-JAK2, p-STAT3 and 
p-STAT5 with the quantification on the intensity of the bands by western blotting in HDLM-2 (C) (n = 3) and L-540 (D) (n = 3) cells. Data 
are represented as the mean ± SD. *p < 0.005; **p < 0.0005; ***p < 0.0001.
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was a significant increase on caspase 3/7 activity at day 2 
with >1.2 fold (p < 0.05), >1.3 fold (p = 0.01), and >1.5 
fold (p < 0.05) increase at 1, 10, and 100 uM of ruxolitinib 
treatment, respectively, in L-428 cells compared to 
DMSO treated control cells. We also observed significant 
increases in caspase 3/7 activity in ruxolitinib treated 
HDLM-2 cells (>1.9 fold, p < 0.05; >2.5, p < 0.001; 
>3.2 fold, p < 0.01 in 1, 10 and 100 uM ruxolitinib, 
respectively). In addition, ruxolitinib significantly induced 
Caspase-3/7 activity in ruxolitinib treated Karpas-1106P 
cells (<1.5 fold, p < 0.01; >1.8 fold, p < 0.01; >2.0 fold, 
p < 0.01 in 1, 10 and 100 uM ruxolitinib, respectively) 
compared to control cells following DMSO treatment in 
Karpas-1106P cells. The cleavage of PARP (Figure 3C) 
and caspase-3 (Figure 3D), another hallmark of apoptosis, 
was significantly increased in ruxolitinib treated L-428 (p 
< 0.001 and p < 0.0005 at cleaved Caspase-3 and PARP, 
respectively), HDLM-2 (p < 0.0005 at both cleaved 
Figure 2: Downregulation of p-STAT3, p-STAT5 and p-STAT6 expression in HL and PMBL by ruxolitinib. Total cell 
lysates were collected treated L-428 (A) and HDLM-2 (B) HL, and Karpas-1106P PMBL cells (C) following ruxolitinib treatment (0, 25, 
100, 400, and 1000 nM), and western blotting of protein expression of p-JAK2, JAK2, p-STAT3, STAT3, p-STAT5, STAT5, p-STAT6 
and STAT6 were performed. (n = 3). Band intensity was quantified by western blot in ruxolitinib treated L-428 (D), *p < 0.0005;**p < 
0.00005;***p < 0.00001) and HDLM-2 (E) HL, and Karpas-1106P PMBL cells (F). Data are represented as the mean ± SD of triplicates 
(paired t test). *p < 0.001;**p < 0.0001;***p < 0.00001. 
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Figure 3: Cell proliferation, Caspase 3/7-dependent apoptosis and cleaved Caspas-3 and PARP in HL and PMBL cells. 
Cells were plated (1x105) into 48 well plates and cell growth was measured every 48 hours via MTS assay following ruxolitinib treatment 
(0, 1, 10 and 100 uM) in L-428 (left) and HDLM-2 (middle) HL cells, and Karpas-1106P PMBL cells (right) (A) (n = 3). Caspase 3/7 
activity was measured using the Clarity Luminescence microplate reader (Biotek) in L-428 (left) and HDLM-2 (middle) HL cells, and 
Karpas-1106P PMBL cells (right) (B) (n = 3). Data are represented as the mean ± SD . *p < 0.05; **p < 0.01; ***p < 0.001. Cleaved Caspas-3 
and PARP protein expression were measured by western blotting in L-428 (left) and HDLM-2 (middle) HL cells, and Karpas-1106P PMBL 
cells (right), and the arrow indicates cleaved Caspas-3 and PARP (C) (n = 3) and the intensity of the bands on gels by western blot was 
quantified in cells (D) (n = 3). Data are represented as the mean ± SD. *p < 0.005; **p < 0.001; ***p < 0.0005.
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proteins) and Karpas-1106P cells (p < 0.005 and p < 
0.0005 at cleaved caspase-3 and PARP, respectively) in 
the same dose-dependent manner following 100 uM of 
ruxolitinib treatment.
Significant changes in the expression of pro- and 
anti-apoptotic protein and gene expression in 
ruxolitinib treated HL and PMBL cells
We also examined the effects of ruxolitinib on 
the expression of pro- and anti-apoptotic proteins to 
enhance our understanding of the effects of ruxolitinib 
on apoptosis in HL and PMBL cells. Cells were treated 
with 100 uM ruxolitinib for 48 hours and the expression 
of anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-
1 were analyzed. There was significant decrease of Bcl-2 
(p < 0.005), Bcl-xL (p < 0.0005) and Mcl-1 (p < 0.0001) 
in 100uM ruxolitinib treated HDLM-2 cells compared 
to DMSO treated cells (Figure 4A). Additionally, we 
observed significant inhibition of the protein expression 
of Bcl-2 (p < 0.0001), Bcl-xL and Mcl-1 (p < 0.0005) 
following 100 uM ruxolitinib exposure to Karpas-1106P 
cells (Figure 4B). We also observed significant inhibition 
of expression of Bcl-2 mRNA in 100 uM ruxolitinib 
treated HDLM-2 (p < 0.0005) and Karpas-1106P cells 
(p < 0.0005) (Figure 4C). Interestingly, ruxolitinib also 
significantly inhibited the expression of Bcl-xL mRNA 
in 100 uM ruxolitinib treated HDLM-2 (p < 0.005) and 
Karpas-1106P cells (p < 0.001) (Figure 4D). These results 
suggest that ruxolitinib decreases HL and PMBL survival 
by in part inducing programmed cell death via down-
regulating the expression of pro- and anti-apoptotic genes 
in HL and PMBL cells. 
Effect of ruxolitinib on survival in PMBL and 
HL xenografted NSG mice
We further examined the efficacy of ruxolitinib in 
L-428 HL cells xenografted NSG mice and in Karpas-
1106P PMBL cells xenografted NSG mice. Most 
importantly, ruxolitinib (45.0 mg/kg) treated L-428 (p 
< 0.03) and Karpas-1106P (p < 0.002) xenograft NSG 
mice had a significantly prolonged survival compared 
to control mice. Finally, we observed that ruxolitinib 
(45.0 mg/kg) treated L-428 xenografted NSG mice (n 
= 16) had significantly prolonged survival time with a 
median of 51.5 days compared to control mice (n = 15) 
(21 days, p = 0.0001) (Figure 5A), along with significant 
prolonged survival in ruxolitinib treated Karpas-1106P 
xenografted NSG mice (n = 16, median of 41.5 days) 
compared to control mice (n = 15, median of 20 days) (p 
< 0.0001) (Figure 5B). Furthermore, we demonstrated a 
significant decrease in L-428 HL and Karpas-1106 PMBL 
in bio-luminescence intensity (tumor burden) following 
ruxolitinib treatment in HL xenografted NSG mice (45.0 
mg/kg, p < 0.05) at day 21 and 28 (Figure 5C), and 
Karpas-1106P PMBL cells xenografted NSG mice (45.0 
mg/kg) (p < 0.05) at day 21 and 28 compared to control 
mice (Figure 5D).
DISCUSSION
We investigated the efficacy of ruxolitinib in HL and 
PMBL cells and found significant in vitro anti-proliferative 
and proapoptotic effects of ruxolitinib treated L-428 
and HDLM-2 HL cells and Karpas-1106P PMBL cells. 
Additionally, we observed significant downregulation in 
the phosphorylation of STAT3, STAT5 and STAT6 in HL, 
and p-STAT3 and STAT6 in PMBL following ruxolitinib 
treatment. Most importantly, ruxolitinib significantly 
decreased tumor burden and prolonged survival in HL and 
PMBL xenografted NSG mice. 
HL and PMBL are highly curable diseases in first 
complete remission; however, patients with relapsed or 
refractory HL and PMBL have typically been associated 
with high failure rates despite aggressive chemo-
radiotherapeutic approaches and/or autologous stem 
cell marrow transplantation [6, 33–35]. Furthermore, 
late effects in both HL and PMBL are significant, which 
affect both morbidity and mortality. Thus, novel salvage 
regimens are needed and less toxic new approaches in 
newly diagnosed patients are also warranted. Patients with 
the myelofibrosis (MF) carrying activating mutant allele 
of JAK2 exhibited rapid, significant reduction in disease 
burden and durable clinical benefit in patients following 
ruxolitinib [31, 36]. 
Ruxolitinib is an orally available pyrrolo [2,3-d] 
pyrimidine analog that exhibits subnanomolar affinity 
for JAK2 and JAK1 but exhibits lower activity against 
JAK3 [30]. Our observations in this study are consistent 
with these findings that ruxolitinib has selective activity 
of JAK2 against JAK3 protein, as demonstrated by 
inhibition of phosphorylation of the downstream STAT3 
and STAT5 proteins at 10-100 nM ruxolitinib in HDLM-
2 JAK2/STAT signaling vs L-540 JAK3/STAT signaling. 
In agreement with earlier studies, increased levels of 
JAK2 phosphorylation were observed despite inhibition 
of downstream STA3, STAT5 and STAT6 signaling in HL 
and PMBL cells. Similar paradoxical phosphorylation 
has been previously reported after incubation with JAK2 
inhibitor Gö6976 and SB1518 in primary acute myeloid 
leukemia cells HEL92.1.7, [37, 38] and JAK inhibitor 
AZD 1480 in HL cells [39]. These findings could be 
related to the induction of negative-feed-back loops 
involving activating cytokines. Suppressor of cytokine 
signaling 1(SOCS1) works as the key effector of a classic 
negative feedback loop in JAK/STAT signaling. SOCS1 
has been identified as a recurrently mutated tumor 
suppressor gene in HL and Karpas-1106P PMBL cells 
[40, 41]. Further, mutated SOCS1 may have contributed 
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to the hyper-phosphorylation of JAK2 in HL and PMBL. 
Finally, ruxolitinib has also been demonstrated to inhibit 
the phosphorylation of ERK1/2, especially downstream to 
RAS-RAF-MEK-ERF signaling pathway [30, 42].
In this study, we demonstrated that ruxolitinib 
significantly inhibits HL and PMBL JAK/STAT signaling 
pathways. Furthermore, ruxolitinib significantly 
suppresses cell proliferation in HL and PMBL cells. This 
is consistent with inhibition of cell proliferation reported 
by Ju et al. in 4 HL cell lines [43]. The half maximal 
inhibitory concentration (IC50) is shown for L-428 (IC50 
= 74.9 uM), HDLM-2 (IC50 = 15.7 uM) and Karpas-
1106P (IC50 = 43.8 uM). Compared to the abrogation of 
downstream STAT phosphorylation by ruxolitinib at sub-
micromolar and micromolar concentrations, relatively 
less sensitive anti-proliferative effects were observed. 
The relatively high IC50 of HL and PMBL cells imply that 
SOCS1 negative-feedback loop may activate secondary 
signaling pathways other than JAK2/STAT in HL and 
PMBL. 
The maximum tolerated dose (MTD) for ruxolitinib 
in MF was established at 25 mg twice daily or 100 mg 
once daily [31, 44]. When investigated in children with 
relapsed/refractory malignancies in a phase 1 consortium 
study by the Children’s Oncology Group at five dose 
levels, ruxolitinib did not exceed the MTD; dose limiting 
Figure 4: Downregulation of pro- and anti-apoptotic proteins and gene expression in HL and PMBL cells. Ruxolitinib 
significantly induced apoptosis through down-regulation of anti-apoptotic proteins, Bcl-2, Bcl-xL and Mcl-1 in ruxolitinib HDLM-2 (A) 
(n = 3) HL and Karpas-1106P PMBL cells (B) (n = 3). The intensity of the bands on gels by western blot was quantified in cells. Data are 
represented as the mean ± SD. *p < 0.005; **p < 0.0005; ***p < 0.0001. Real time qRT-PCR expression levels of Bcl-2 mRNA (C) (n = 3) 
and Bcl-xL mRNA (D) (n = 3) in ruxolitinib treated HDLM-2 HL cells and Karpas-1106P PMBL cells are shown. GAPDH was used as 
endogenous control for qRT-PCR normalization. *p < 0.01;**p < 0.005; ***p < 0.0005.
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toxicity (DLT) was observed in ≤1 of 6 patients per cohort 
[45]. In a phase I/II study of ruxolitinib in patients >14 
years old with relapsed/refractory acute myeloid leukemia 
(AML), ruxolitinb was reasonably well tolerated in doses 
ranging from 50 mg twice daily to 200 mg twice daily 
[46]. In the present study, while we saw some effects at the 
lower concentration, the effect was augmented with higher 
dosing. These findings, with the relatively high IC50 in HL 
and PMBL cells in our study, suggest that higher dosing 
of ruxolitinib may be necessary for optimum activity, and 
may be well tolerated. 
A kinetic analysis of caspase 3/7 activity following 
ruxolitinib therapy in HL and PMBL cells revealed that 
ruxolitinib significantly activates caspase 3/7 and induces 
apoptosis. This is in part presumably secondly to down- 
regulating the expression of anti-apoptotic factors, 
Figure 5: Survival in ruxolitinib treated HL and PMBL xenografted NSG mice. Survival rates were analyzed following 
ruxolitinib treatment (45 mg/kg) by Kaplan-Meier method and differences evaluated by log-rank test. A significant difference in ruxolitinib 
treated L428 HL cells xenografted NSG mice (n = 16) compared to control (n = 15, p = 0.0001) (A). Ruxolitinib treated Karpas-1106P 
xenografted NSG mice (n = 16) had significantly extended survival time compared to the control mice (n = 15, p < 0.0001) (B). A 
significant decrease in tumor luminescence intensity following ruxolitinib treated HL 28 (45 mg/kg, p < 0.05) (C) and PMBL (45 mg/kg) 
(p < 0.05) xenografted NSG mice (D) at day 21 and compared to control.*p < 0.05.
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such as Bcl-2 and Bcl-xL in HL and PMBL cells. Our 
results suggest that therapy with ruxolitinib significantly 
decreased tumor burden and prolonged survival in HL and 
PMBL xenografted NSG mice. This is consistent with 
in vitro and in vivo JAK2 inhibition in HL and MLBL 
using fedratinib [26, 29]. Kim et al. demonstrated in 
a phase I study the safety and efficacy of ruxolitinib in 
adult patients with HL and PMBL, with disease control 
achieved in 54% (7/13) patients with heavily pretreated 
relapsed or refractory HL [47]. Most recently, Neste et al. 
demonstrated in a phase II study, a best ORR (1 CR/5 
PR) of 19% (6/32) of ruxolitinib in adults with relapsed/
refractory HL [48]. These results are consistent with our 
preclinical studies of mild to modest activity.
In summary, we have demonstrated that ruxolitinib, 
a JAK1/JAK2 inhibitor, significantly blocks in vitro STATs 
signaling, induces apoptosis and inhibits cell proliferation 
in vitro against HL and PMBL cell lines and in vivo 
prolonged survival in HL and PMBL xenografted NSG 
mice. Thus ruxolitinib has the potential to be an alternative 
therapeutic strategy in patients with high risk HL and 
PMBL. In PMBL, in addition to gains of chromosome 
9p (including JAK2, JMJD2C, PDL1, PDL2), gain of 
chromosome 2p (including REL, BCL11A) has been 
consistently reported in up to 50% of patients [49, 50]. 
Gains of the same regions are also detected in HL [19, 51]. 
These genetic features suggest that there may be options to 
improve the therapeutic effect of ruxolitinib by combining 
it with other targeted therapies such as PD-1 or PDL-1 
blockades or brentuximab-vedotin, in cHL [26, 43]. 
Future studies will be required to determine how 
best to incorporate this therapeutic agent in both newly 
diagnosed high risk and in relapsed/refractory patients 
with both HL and PMBL.
MATERIALS AND METHODS
Cell lines
The HL cell lines HDLM-2, L-428, L-540 and 
PMBL cell line Karpas-1106P cells were obtained from 
the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Germany). All of these 4 cell lines 
were previously demonstrated to have a significant 
9p24.1 and JAK2 amplification [25]. The L-428 cells 
were cultured in RPMI 1640 medium supplemented with 
10% heat-inactivated fetal bovine serum (GIBCO BRL, 
Gaithersburg, MD, USA) 1% glutamine and penicillin-
streptomycin in a humid environment of 5% CO2 at 37° C. 
The HDLM-2, L-540 and Karpas-1106P cell lines were 
cultured in RPMI 1640 medium supplemented with 20% 
heat-inactivated fetal bovine serum.
Cell proliferation assay 
Cell growth was determined by the Cell titer 
96 Aqueous One solution cell proliferation assay 
(MTS) (Promega, Madison, WI). At 24, 48 and 72 
hours after treatment with INC424 or DMSO, MTS 
reagent was added and cells were incubated for 1 
hour at 37° C. Cell proliferation was measured by 
OD 490 nm using Multilabel Counter (Perkin Elmer, 
Massachusetts, USA).
Caspase 3/7 assay
Caspase 3/7 activity was directly measured at 
24, 48 and 72 hours after treatment using Caspase-Glo 
3/7 Activity kit (Promega) as per the manufacturer’s 
protocol. Briefly, the cells (5 × 105/ml) were seeded 
into 24-well plated and treated with vehicle (DMSO) 
alone or ruxolitinib at various concentrations for 48 
and 72 hours, Caspase-Glo reagent was added and cells 
were incubated for 1 hour at room temperature in the 
dark. Relative light intensity was measured in each well 
using Clarity Luminescence microplate reader (BioTek, 
Vermont, USA).
Reagents and antibodies
Ruxolitinib (INC424) was generously provided by 
Incyte Corporation (Wilmington, DE, USA. AG-490). 
Antibodies specific for phospho-JAK3, JAK3, STAT3, 
STAT5, were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Antibodies specific for phospho-
STAT3, phospho-STAT5, phospho-STAT6, STAT6, 
phospho-JAK2, JAK2, Bcl-xL, Bcl-2, Mcl-1, Caspas-3, 
poly adenosine diphosphate ribose polymerase (PARP) 
were purchased from Cell Signaling Technology 
(Cambridge, MA, USA). 
Western blot analysis
Cell pellets were suspended in a lysis buffer 
containing 50 mmol/l Tris–HCl, pH 7.4, 350 mmol/l 
NaCl, 1% TritonX-100, 0.5% Nonidet P-40, 10% 
glycerol, 0.1% sodium dodecyl sulfate (SDS), 1 
mmol/l EDTA, 1 mmol/l EGTA, 1 mmol/l Na3VO4, 
1 mmol/l phenylmethylsulphonyl fluoride (PMSF) 
and phosphatase inhibitor cocktails on ice. Whole-
cell extracts were resolved on SDS-PAGE, transferred 
to nitrocellulose membrane, and probed with 
appropriate antibodies. Membranes were blocked 
in 5% non-fat dried milk in Tris-buffered saline (pH 
7.4) containing 0.1% Tween 20 (TBST) for 1 hour 
and subsequently incubated with primary antibodies 
diluted in TBST at 4° C overnight. Membranes were 
then probed with horseradish Peroxidase-conjugated 
secondary antibodies and developed using enhanced 
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chemiluminescence (ECL) reagent (GE Healthcare Bio-
Sciences, Piscataway, NJ, USA). Band intensities on 
SDS-PAGE gel were measured using ImageJ software 
program [52].
Quantitative reverse-transcriptase polymerase 
chain reaction (qRT-PCR)
Total RNA was prepared using Trizol reagent (Invitrogen) 
according to the manufacturer’s directions, and cDNA was 
synthesized using qScript™ cDNA Synthesis Kit (Quantas) 
using 1ug of RNA. The qRT-PCR was performed using CFX96 
Real-time system (Bio-rad) and SsoFast™ EvaGreen® Supermix 
(Bio-rad) as PCR reagents. Relative quantification (ddCt) of 
mRNA expression of genes was determined by normalizing to 
the housekeeping gene (GAPDH). Primers used in qRT-PCR are 
previously described [53].
In vivo xenograft mouse models
The experimental animal protocols, procedures 
and care were approved by the Institutional Animal 
Care and Use Committee at New York Medical College 
(NYMC), Valhalla, NY, USA. Kapas-1106P PMBL cell 
line and L-428 HL cell line were stably transfected with 
a firefly luciferase expression plasmid (ffluc-zeo), kindly 
provided by Laurence Cooper MD, PhD, and then stable 
clones were selected under zeocin (Invitrogen) selection. 
The mice were γ-irradiated (2.5 Gy) 1 day before tumor 
cell transplantation. Six- to eight- week-old female NSG 
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (The Jackson 
laboratory, Bar Harbor, ME) were subcutaneously injected 
with 1 × 106 ffluc-zeo Karpas-1106P or L-428 cells. The 
tumor burden was verified by bioluminescence imaging 
(BLI) system using the Xenogen IVIS-200 (Caliper 
Life Sciences) for up to 50 days as we have previously 
described [54]. Mice were orally gavaged with either 0.5% 
methyl cellulose vehicle or ruxolitinib (45.0 mg/kg) for 
21 days. Tumor progression was monitored at day 7 and 
once every week by BLI. The survival rate was analyzed 
using humane endpoints and all mice were sacrificed when 
tumor size was greater than 2.0 cm3 ([length × width2]/2]) 
or with signs of ulceration, or if mice were moribund. 
Statistical analysis
Data obtained from independent experiments 
are represented as means ± standard deviation (SD) 
and significant differences between two groups were 
determined by using Student’s t-test. Statistical analysis 
was performed using a two-tailed Student’s t test. P values 
less than 0.05 were considered significant. In vivo study, 
survival rates were analyzed by the Kaplan-Meier method 
and differences evaluated by log-rank test using the Prism 
Version 6.0 software. 
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